Trial of Galcanezumab in Prevention of Episodic Cluster Headache | Zendy

Peter J. Goadsby | Zendy; David W. Dodick | Zendy; Massimo Leone | Zendy; Jennifer Bardos | Zendy; Tina M. Oakes | Zendy; Brian A. Millen | Zendy; Chunmei Zhou | Zendy; Sherie A. Dowsett | Zendy; Sheena K. Aurora | Zendy; Andrew H. Ahn | Zendy; Jyun-Yan Yang | Zendy; Robert R. Conley | Zendy; James M. Martinez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trial of Galcanezumab in Prevention of Episodic Cluster Headache

Author(s) -

Peter J. Goadsby,

David W. Dodick,

Massimo Leone,

Jennifer Bardos,

Tina M. Oakes,

Brian A. Millen,

Chunmei Zhou,

Sherie A. Dowsett,

Sheena K. Aurora,

Andrew H. Ahn,

Jyun-Yan Yang,

Robert R. Conley,

James M. Martinez

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1813440

Subject(s) - cluster headache , medicine , placebo , cluster (spacecraft) , clinical endpoint , clinical trial , anesthesia , migraine , alternative medicine , pathology , computer science , programming language

Episodic cluster headache is a disabling neurologic disorder that is characterized by daily headache attacks that occur over periods of weeks or months. Galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research